European Commission Approves Tocilizumab for Treatment of Giant Cell Arteritis

SEPTEMBER 22, 2017
Jenna Payesko
Giant Cell Arteritis, Tocilizumab, Actemra/RoActemraThe European Commission (EC) has approved tocilizumab (Actemra/RoActemra) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition, Roche announced.

Actemra/RoActemra is the first GCA treatment therapy approved in Europe. The approval was based on the outcome of the phase 3 GiACTA study.

“We are delighted that Actemra/RoActemra has been approved for the treatment of GCA in Europe,” said Sandra Horning, MD, chief medical officer, global head of product, Roche. “As the first effective non-steroid therapy for GCA, Actemra/RoActemra has the potential to fundamentally change how this condition is treated.”

The phase 3 study, NCT01791153, investigated the efficacy and safety of Actemra/RoActemra as a novel treatment for GCA. It’s the largest clinical trial conducted in GCA and the first to use blinded, variable-dose, variable-duration steroid regimens. The multicenter study was conducted in 251 patients, across 76 sites in 14 countries.

Study results showed that a weekly dose of Actemra/RoActemra, initially combined with a 6-month steroid taper, significantly increased the proportion of patients achieving sustained remission at 1 year, 56%, compared to a 6-month steroid taper given alone, 14%. Primary and secondary endpoints were evaluated at 52 weeks.

An extension study, NCT03202368, to the phase 3 GiACTA study will evaluate long-term safety of subcutaneous tocilizumab in participants with GCA who subsequently have flare or persisting disease activity. A maximum of 11 participants from 6 centers in France that participated in the phase 3 study will be enrolled in the 160-week study. The estimated primary completion date is December 2018.

Treatment to date is limited to high-dose steroids that are an effective emergency treatment option to prevent damage like vision loss, however, in some cases steroids are unable to maintain long-term disease control.

In May 2017, Actemra/RoActemra was approved for treatment by the US Food and Drug Administration (FDA) and New Zealand’s Medsafe.
 
Results of the phase 3 study were published in the New England Journal of Medicine in July 2017.

A press release was made available.

Related Coverage
First Drug to Specifically Treat Giant Cell Arteritis Gains FDA Approval
How Long Should Tocilizumab Be Continued for Patients with Giant Cell Arteritis?
Guselkumab 2-Year Data Shows Positive Results for Plaque Psoriasis Patients

Copyright© MD Magazine 2006-2017 Intellisphere, LLC. All Rights Reserved.